Author(s)

Wang Le ¹, Jin Gaowa ², Li Quanfu ², Ren Xiaojuan ², Jiang Ying ², Deng Shuqin ²

Affiliation(s)

¹ Ordos Clinical College, Inner Mongolia Medical University, Ordos, Inner Mongolia, China
² Department of Oncology, Ordos Central Hospital, Ordos, Inner Mongolia, Ordos, Inner Mongolia, China

Corresponding Author

Li Quanfu

ABSTRACT

Previous literature mainly focused on the application status of patient-reported outcomes in various medical fields and the research progress of PRO measurement tools at home and abroad. However, there is a lack of summary on the clinical research and practical application of PRO in gastrointestinal tumors. In view of this, this paper aims to discuss the application status and research progress of PRO in the clinical treatment practice of gastrointestinal tumors, in order to provide useful reference for future related studies.

KEYWORDS

Patient-reported outcomes; Gastrointestinal tumor; Patient-reported outcome measures; summarize

CITE THIS PAPER

Wang Le, Jin Gaowa, Li Quanfu, Ren Xiaojuan, Jiang Ying, Deng Shuqin, Application status and research progress of PRO in clinical tumor. MEDS Clinical Medicine (2024) Vol. 5: 101-105. DOI: http://dx.doi.org/10.23977/medsc.2024.050413.

REFERENCES

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May; 71(3):209-249.
[2] Zhang X, Liang H, Li Z, Xue Y, et al; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug; 22(8):1081-1092. doi: 10.1016/S1470-2045(21)00297-7.
[3] Wu H, Zhang M, Chen X. Research Application of Patient-Reported Outcomes in Assessing the Nutritional Status of Patients with Gastrointestinal Tumors[J].Journal of Clinical and Nursing Research, 2022, 6(3):197-203.
[4] Was H, Borkowska A, Bagues A, et al. Mechanisms of Chemotherapy-Induced Neurotoxicity. Front Pharmacol. 2022 Mar 28;13:750507. doi: 10.3389/fphar.2022.750507. 
[5] Lemonnier I, Guillemin F, Arveux Pet al. Quality of life after the initial treatments of non-small cell lung cancer: a persistent predictor for patients' survival. Health Qual Life Outcomes. 2014 May 15; 12:73. doi: 10.1186/1477 -7525-12-73. 
[6] Dennison CR (2002) The role of patient-reported outcomes in evaluating the quality of oncology care. Am J Manag Care 8: S580–S586.
[7] Howell D, Molloy S, Wilkinson K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015; 26(9):1846-1858.
[8] Besson A, Deftereos I, Chan S,et al. Understanding patient-reported outcome measures in colorectal cancer. Future Oncol. 2019 Apr;15(10):1135-1146. doi: 10.2217/fon-2018-0723. Epub 2019 Mar 18. 
[9] Kerrigan K, Patel SB, Haaland B, Ose D, et al. Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncol Pract. 2020 Apr;16(4): e313-e323. 
[10] Silveira A, Sequeira T, Gonçalves J, et al. Patient reported outcomes in oncology: changing perspectives-a systematic review. Health Qual Life Outcomes. 2022 May 21;20(1):82.
[11] Andre T, Amonkar M, Norquist JM, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 May;22(5):665-677.
[12] Lordick F, Al-Batran SE, Ganguli A,et al. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma[J]. Gastric Cancer, 2021, 24(3):721-730. DOI: 10.1007/s 10120-020-01153-6.
[13] Mayor S. Doctors less likely than patients to report toxicity of cancer treatments, study shows. BMJ. 2015 Jan 27; 350:h485.
[14] Silveira A, Monteiro E, Sequeira T. Head and neck cancer: improving patient-reported outcome measures for clinical practice. Curr Treat Options Oncol. 2018. 
[15] Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007 Sep-Oct; 57(5):278-300.
[16] Varker KA, Ansel A, Aukerman G, et al. Review of complementary and alternative medicine and selected nutraceuticals: background for a pilot study on nutrigenomic intervention in patients with advanced cancer[J].Altern Ther Health Med, 2012,18(2):26-34.
[17] Sodergren SC, Husson O, Robinson J, et al; EORTC Quality of Life Group. Systematic review of the health-related quality of life issues facing adolescents and young adults with cancer. Qual Life Res. 2017 Jul; 26(7):1659-1672.
[18] Aune D, Deneo-Pellegrini H, Ronco AL, et al. Dietary folate intake and the risk of 11 types of cancer: a case-control study in Uruguay. Ann Oncol off J Eur Soc Med Oncol. 2011; 22: 444-451.
[19] Gonzalez-Palacios S, Compañ-Gabucio LM, Torres-Collado L, et al. The protective effect of dietary folate intake on gastric cancer is modified by alcohol consumption: A pooled analysis of the StoP Consortium. Int J Cancer. 2024 Oct 15; 155(8):1367-1375. doi: 10.1002/ijc.35004. Epub 2024 May 16.
[20] Mitchell KR, Brassil KJ, Fujimoto K, et al. Exploratory Factor Analysis of a Patient-Centered Cancer Care Measure to Support Improved Assessment of Patients' Experiences. Value Health. 2020 Mar; 23(3):351-361.
[21] FDA. Clinical Outcome Assessment (COA): Frequently Asked Questions[J/OL]. FDA, 2020. https:// www.fda. gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions.
[22] Williamson S, Beaver K, Gardner A, et al. Telephone follow-up after treatment for endometrial cancer: A qualitative study of patients' and clinical nurse specialists' experiences in the ENDCAT trial. Eur J Oncol Nurs. 2018 Jun; 34:61-67.

Sponsors, Associates, and Links

---

• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Basic Medicine
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine